Novartis reinvested in Annexon, which is developing treatments for neurodegenerative diseases, and which has now raised $79m in total.
Annexon Biosciences, a US-based developer of treatments for neurodegenerative disorders, completed a $44m series B round yesterday that included pharmaceutical firm and Novartis.
Novartis, which participated through its Novartis Venture Fund subsidiary, was joined by venture capital firm New Enterprise Associates, which led the round, as well as Correlation Ventures, Clarus Ventures and Satter Investment Management.
Annexon is working on therapies intended to combat neurodegenerative disorders like Alzheimer’s disease and Huntington’s disease by stopping the progression of complement-mediated neurodegeneration. Its…
